A phase 3 trial of 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) in advanced solid tumours, run by National Vaccine and Serum Institute, China, now recruiting.
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years is a phase 3 interventional study registered as NCT05262010 by National Vaccine and Serum Institute, China, with 13500 participants planned, started 2022-06-04 and due to reach its primary completion in 2028-06. Interventions recorded: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) and placebo.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.